Food and Drug Administration staff provided their analysis of Johnson & Johnson’s COVID-19 booster application today, indicating that a second dose provides substantially more protection against SARS-CoV-2 than the initial shot. The analysis is among a trove of data that will be considered this week by the agency’s Vaccines and Related Biological Products Advisory Committee. According to FDA’s analysis, a second, booster dose of the J&J vaccine yielded a 94% efficacy against moderate-to-severe COVID-19; data indicates that the first dose’s efficacy is 70%.

Related News Articles

Headline
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…
Chairperson's File
Working in health care delivery can be stressful and tiring under normal circumstances. And the COVID-19 pandemic has exerted incredible pressures on the…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…